Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

NCT04373031 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Neoplasms

Interventions

DRUG: Pembrolizumab
DRUG: IRX 2

Sponsor

Providence Health & Services

Collaborators

[object Object]
[object Object]